bioanticipation
Posted - 2 days ago
$TVTX you’re welcome
First_Class_Seaman
Posted - 6 days ago
$TVTX nice looking chart
$SUGP Friday AH action was solid. Will continue into Moonday morning.
OpenOutcrier
Posted - 1 week ago
$TVTX (-5.4% pre) Travere Therapeutics (TVTX) Prices 7.81M Share Offering at $16/sh - SI https://ooc.bz/l/47389
DonCorleone77
Posted - 1 week ago
$TVTX Travere Therapeutics announces common stock offering, no amount given Travere Therapeutics announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, shares of its common stock. All of the shares are being offered by Travere. Jefferies and Leerink Partners are acting as the joint book-running managers for the offering.
Kennedy_P
Posted - 1 week ago
🚨 MYNZ HUGE PR drop incoming before the Nov 13 meeting 🔥 Someone is pushing these dates of upcoming NEWS 3 biggest stock alert channels announced, might consider to add now, who knows. $TVTX $ARDX
GreenwichCapital
Posted - 2 weeks ago
$TVTX short term volatility long term very bullish.
DonCorleone77
Posted - 2 weeks ago
$TVTX Travere Therapeutics price target raised to $20 from $18 at Barclays Barclays raised the firm's price target on Travere Therapeutics to $20 from $18 and keeps an Overweight rating on the shares post the Q3 report. The firm says Filspari beat despite a slow-down in new starts.
smalltraderjoe
Posted - 10/31/24
$TVTX I have been holding it for months , the kiss of 18 is not good for it
astroplane
Posted - 10/31/24
$TVTX I thought revenue would be higher.
DonCorleone77
Posted - 10/31/24
$TVTX Travere Therapeutics reports Q3 adjusted EPS (46c), consensus (68c) Reports Q3 revenue $62.9M, consensus $60.48M. "Our performance in the third quarter was exceptional. FILSPARI received full approval as the only medicine that can provide superior preservation of kidney function and replace current standard of care in IgAN, and our commercial team delivered strong growth in sales of FILSPARI in the U.S. Additionally, I am pleased to report that in the weeks since full approval we have seen a meaningful increase in demand, supporting our expectation that the broader label granted upon full approval coupled with the recent draft KDIGO guidelines will strengthen FILSPARI's growth," said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. "As we look ahead, we are very well-positioned to further accelerate our growth with FILSPARI. At ASN Kidney Week, we illustrated the potential benefits of using FILSPARI as a first-line treatment, and presented data in combination with other therapies. Our European partner CSL Vifor has launched FILSPARI commercially in the first EU countries. And following the recent PARASOL group recommendation of a proteinuria-based clinical trial endpoint for FSGS, we have scheduled a meeting with the FDA to discuss a potential path forward for FILSPARI in FSGS."
Rumrunner5
Posted - 10/31/24
$TVTX Lets go up this morning !
IN0V8
Posted - 10/30/24
$TVTX Opportunity Jefferies raises target price to $33 from $17
Estimize
Posted - 10/28/24
Wall St is expecting 61.93% YoY revenue growth for $TVTX in Q3, up from -9.34% in Q2 [Reporting 11/06 AMC]
http://www.estimize.com/intro/tv
DonCorleone77
Posted - 10/27/24
$TVTX Travere presents data reinforcing clinical benefit of FILSPARI in IgAN Travere Therapeutics presented new data further demonstrating the clinical benefit of FILSPARI in IgA nephropathy and reinforcing its potential in focal segmental glomerulosclerosis at the American Society of Nephrology Kidney Week 2024. Key findings from the PROTECT study subgroup analysis of patients with proteinuria above and below 1 g/g: FILSPARI delivered superior proteinuria reduction, and complete proteinuria remission earlier and more frequently compared to irbesartan regardless of baseline UPCR, including those at less than 1.0 g/g. Key Findings from the SPARTAN study evaluating FILSPARI as a first-line therapy: FILSPARI delivered a rapid and sustained reduction in proteinuria of approximately 70% from baseline over 24 weeks in newly diagnosed, RASi-naive patients, and nearly 60% of patients in the SPARTAN study achieved complete remission of proteinuria at any point in time during the treatment period. Throughout the 24 weeks, estimated glomerular filtration rate was stable. Key Findings from the SPARTACUS Study, PROTECT OLE and Real-World Use Evaluating FILSPARI in Combination Therapy for IgAN Interim data from the SPARTACUS Study demonstrated that FILSPARI, when added to stable SGLT2i, was generally well tolerated. Approximately one-third of patients had their proteinuria reduced by at least 50%, and two-thirds of patients by at least 30% when measured after 24 weeks of treatment. Data from the ongoing PROTECT Study open-label extension and real-world use showed favorable safety and additive efficacy results when SGLT2i or immunosuppressants were combined with foundational FILSPARI treatment. Key Findings from the DUPLEX Study Evaluating Sparsentan in Focal Segmental Glomerulosclerosis In a late-breaking presentation from the DUPLEX Study in a subset of patients with genetic mutations in podocyte proteins, a high-risk, treatment resistant FSGS, sparsentan delivered a rapid and sustained proteinuria reduction, including some patients who achieved complete remission and long-term kidney health benefits. An analysis of patient-reported outcomes from 306 adult patients in the DUPLEX Study showed that health-related quality of life for these patients with FSGS on sparsentan was stable over the two-year treatment period, and that patients' burden of kidney disease was improved compared to those receiving irbesartan. Key Findings from the EPPIK Study Evaluating Sparsentan in Rare Proteinuric Disease in Pediatric Patients Preliminary data from the EPPIK Study showed that children with a range of rare proteinuric glomerular disease treated with sparsentan experienced rapid and robust proteinuria reduction of approximately 50% over 12 weeks.
swingingtech
Posted - 10/22/24
$TVTX
https://wallstreetwaves.com/wells-fargo-boosts-rating-for-travere-therapeutics-tvtx/
Mattedbumhair
Posted - 10/21/24
$TVTX wow
GreenwichCapital
Posted - 4 weeks ago
$TVTX
thehivemindfund
Posted - 4 weeks ago
$TVTX It’s overheated, for one thing. If it comes down a bit more, I’ll re-enter.
smalltraderjoe
Posted - 4 weeks ago
$TVTX Why the hell it is 11% down AH ? Any idea?
briefingcom
Posted - 4 weeks ago
$TVTX: Travere Therapeutics and CSL Vifor announce that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241017071526TVTX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
OpenOutcrier
Posted - 1 month ago
$TVTX (+1.9% pre) Travere Therapeutics (TVTX) and CSL Vifor Announce Swissmedic Approval of FILSPARI - SI https://ooc.bz/l/44981
themacromindset
Posted - 1 month ago
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy $TVTX
swingingtech
Posted - 1 month ago
$TVTX $CSL $CSLLY
https://wallstreetwaves.com/csl-vifor-and-travere-therapeutics-announce-swissmedic-approval-of-filspari-sparsentan-for-t
GhostxSwings
Posted - 1 month ago
$TVTX very suspicious orders here. Either news or buy out potential. Mainly all leaps
Mattedbumhair
Posted - 1 month ago
$TVTX will be bought out like ctic
themacromindset
Posted - 1 month ago
$TVTX Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
feefandodie
Posted - 1 month ago
$TVTX I don't know much, but this feels like someone knows something....
feefandodie
Posted - 1 month ago
$TVTX @DonCorleone77 You're as good as I've come across on ST, thanks for all you do and the knowledge sharing. Certainly no expectarepls here, just curious if you have any thoughts on the short term here .
Respectfully
